Accession Number : ADA235385


Title :   Combined Therapy of Septicemia with Ofloxacin and/or Synthetic Trehalose Dicorynomycolate (S-TDCM) in Irradiated and Wounded Mice (Die Kombinierte Therapie der Septikaemie mit Ofloxacin und/oder Synthetischem Trehalose- Dicorynomycolat (S-TDCM) bei Bestrahlten und Verwundeten Maeusen)


Corporate Author : ARMED FORCES RADIOBIOLOGY RESEARCH INST BETHESDA MD


Personal Author(s) : Madonna, Gary S. ; Moore, Mary M. ; Ledney, G. D. ; Elliot, Thomas B. ; Brook, Itzhak


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA235385


Report Date : 1989


Pagination or Media Count : 7


Abstract : Following lethal irradiation, mice usually succumb to sepsis as a result of translocation of intestinal bacteria and impairment of the host defense system. Additional trauma in these immunocompromised mice further increases susceptibility to bacterial infection from either endogenous of exogenous origin. Treatment with ofloxacin or synthetic trehalose dicorynemycolate (S-TDCM) and was evaluated in mice, which were lethally irradiated and wounded, and which died with sepsis within six days. Wounding was performed on C3H/HeN mice anesthetized by inhalation of methoxyfurane. Dorsal skin and muscle equal to 30% total body surface was removed 1 h after 8.0 Gy gamma radiation. S-TDCM, which augments nonspecific resistance to infection in irradiated mice, was given once i.p. immediately after wounding. Oxfloxacin was injected s.c. daily from day 0 to day 10. Staphylococcus aureus, Streptococcus faecium, and Escherichia coli were isolated from both the livers and wound sites of moribund, untreated mice 4 and 5 days postirradiation.


Descriptors :   *CHEMOTHERAPY , *SEPTICEMIA , GAMMA RAYS , WOUNDS AND INJURIES , LETHALITY , IRRADIATION , MICE , LIVER , INFECTIOUS DISEASES , BACTERIAL DISEASES , STREPTOCOCCUS , RESISTANCE(BIOLOGY) , INHALATION , SEPSIS , TRANSLOCATION , STAPHYLOCOCCUS AUREUS , ENTERIC BACTERIA , TREHALOSE , ESCHERICHIA COLI , SURFACES


Subject Categories : MEDICINE AND MEDICAL RESEARCH
      PHARMACOLOGY


Distribution Statement : APPROVED FOR PUBLIC RELEASE